Rebekah Cloud
Family · London, KYNPI 1295378792
Payments from drug & device makers
Across 256 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$623
- Lilly USA, LLC$601
- Novo Nordisk$238
- Johnson & Johnson$237
- Amgen$198
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,15196%
- Education$1794%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 73 | $1,012 |
| AstraZeneca(2 entities) | 28 | $623 |
| Lilly USA, LLC | 44 | $601 |
| Novo Nordisk | 12 | $238 |
| Johnson & Johnson | 14 | $237 |
| Amgen | 11 | $198 |
| Bayer | 12 | $187 |
| Astellas Pharma US Inc | 2 | $179 |
| Sanofi-aventis U.S. LLC | 6 | $132 |
| Otsuka America Pharmaceutical, Inc. | 6 | $119 |
| GSK | 7 | $115 |
| Merck | 6 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $107 |
| Amarin Pharma, Inc. | 7 | $100 |
| Novartis | 5 | $87 |
| Insulet Corporation | 2 | $48 |
| Lundbeck LLC | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $29 |
| Boehringer Ingelheim | 2 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$4,330 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 94 | $129,555 |
| OzempicSemaglutide | 50 | $48,991 |
| TrulicityDulaglutide | 25 | $26,135 |
| VraylarCariprazine Hcl | 18 | $25,598 |
| JardianceEmpagliflozin | 22 | $25,452 |
| EliquisApixaban | 18 | $24,213 |
| FarxigaDapagliflozin Propanediol | 22 | $23,431 |
| LinzessLinaclotide | 33 | $19,617 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $17,832 |
| TrulancePlecanatide | 16 | $15,454 |
| KerendiaFinerenone | 14 | $13,601 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $11,873 |
| RybelsusSemaglutide | 11 | $10,469 |
| XareltoRivaroxaban | 12 | $6,689 |
| Repatha SureclickEvolocumab | 11 | $6,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $601 | $155,690119 claims |
| Novo NordiskOzempic, Rybelsus | $238 | $59,46061 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,012 | $46,29063 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $623 | $41,26351 claims |
| Boehringer IngelheimJardiance | $26 | $25,45222 claims |
| PfizerEliquis | $17 | $24,21318 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $107 | $15,45416 claims |
| BayerKerendia | $187 | $13,60114 claims |
| Johnson & JohnsonXarelto | $237 | $6,68912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.
Other family in London
- Robin HouseLondon$12K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.